Fragile X Syndrome (Homo sapiens)

From WikiPathways

Revision as of 08:08, 18 June 2019 by Fehrhart (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search
P7938637134878895222227232022398232797683794144922391413, 1758797679768124, 40237941235924544740599236403567679889124582333, 913623699247934780941252565, 794847502541Defective cAMP productionAnterior cingulate cortexOther targetsNMDARinternalizationGABA A Receptor SubunitsFXS:loss of FMRPBasolateral AmygdalaNMDA ReceptorPoolNMDARsubunitsstalled polyribosomes7526RISC ComplexGABAergic synapse components59Dysregulated metabolic homeostasis53, 97TSC complex PKAeIF4F complexmGluR-LTD35Receptor subunitsHippocampus CA190AMPA ReceptorEnteric innervation of the ileum42upregulationTrkB ReceptorLTD proteins160ClathrinNMDA ReceptorAMPAR internalizationAMPA Receptor PoolDysregulation of GABAergic synaptic transmissiondeletionrelease of Ca2+Lipid and glucose metabolsim53AP-2Group I mGluR47mTORC170GDPMMP9KCNC1HCN1SRCHOMER1FYNGRM5glutamateGRIN2ADUSP3BDNF-TrkB SignallingCNR1GRIN2AEPS8L1EEF1A1CYFIP2GABRDKCND2494ABAT64PI3K-Akt-mTOR Pathway19CAMKIV-CREB PathwayglutamateBDNFAP2A1PLCB1GAD1cAMPCLTCL1PPP3CAGRIP2CREB1DLG4DLG42, 16SLC6A157PRKCAGAD114PRKACAMEK-ERK-Mnk1 Pathway19EIF4G1ALDH5A111γ-aminobutyric acid73SHC1GRIA1CLTCAP2B1CPT1APRKACAPIP2PTPN5GRB2CLTBGPHN77GRIP1DLG4GRIA2APPmiR-125bCAMK4CREB1PTPN11GRIA1AP2S1AGO2AKAP546GABRG2CAMK1ARHGAP3210GAB1GABRA1PTPN53, 33Dynamin-1DICER16AP2M1PICK1DAG1GRIN2B76, 82GABRB2endocannabinoidsNTRK2SLC16A1CLTAGRIA2SYNGAP1ITPR1PPP1CA51PLCG1CAMK2BSHANK1DLG4DLGAP3MAP2K2FMR13MAP1BARCMKNK1RPS6KB1MAP1B3MAPK1KRASCYFIP112AKT1S1ARC52MAP2K1CAMK2ASOS113PPP2R5BEIF4EBP2RAF1NF115EIF4ECAMK2A72, 87FMR1DEPTORTELO2RPTORMLST8MTORPIK3CBTTI1GRM5RHEBHOMER1GRM1PDK1AGAP2PIP2PTENTSC1AKT1PIP3TSC2TBC1D7RHEBGTPP at Ser500KRASGDPGTPPPPPPDLGAP329, 89SHANK162GRIN2BGRIN2B31GABRA1GABRB2GABRG2GPHNSLC6A1ABATALDH5A1ALDH3A2ABCD3TECRCPT1A53, 67SLC16A153ALDH3A253, 55ABCD366TECR96PPRKAR1APRKAR1APFMR1Influx Ca2+GRIA1GRIA2AMPA ReceptorPGRIA2GRIA146GRIA1GRIA2miR-132miR-196aSH3GL1DNM217260360PP at Thr308EIF4A1TARBP2EIF4EBP254MECP274EPHA41GRIN2ACDKN2AHOXB8MAP2K2MAP2K1MAPK1MKNK1BRAFARAFPSH3GL3mGluR-LTPAMPA ReceptorAMPAR exocytosis46730385downregulation535353NMDARLTD61PKAPRKACAPRKACAPRKAR1APRKAR1AAPP21, 4534Cerebellar cortex43Amygdala23, 42, 94Corticostriatal synapse42Neocortical layer5 neurons42Audiogenic seizures42C-fiber innervation42Suprachiasmatic nucleus42372133GRIN2B76P at Y1472PAP-2AP2A1AP2B1AP2S1AP2M1ClathrinCLTCL1CLTCCLTB22CLTAGRIN2B76overactivationSomatosensoryCortexStriatumSubiculum Hippocampus CA1PTENPTEN6868GRIN1GRIN1DUSP38686NMDARLTPNMDARintsertionEEF1A1CYFIP2GABRD34GRM5HCN1KCNC1KCND2MMP9PRKCAPPRAP1GAP18, 84PEPS8L185PSHANK1PTPN562MAP1B3, 333PTPN53, 33DUSP386hypofunction


Description

Fragile X syndrome (FXS) is a monogenetic disorder cause by a mutation in the FMR1 gene and the most common form of inherited intellectual disability and autism spectrum disorder (ASD). Patients with FXS show a range of typical physical features such as macro-orchidism in males, a long and narrow face, large and protruding ears and hyperextensible joints. Common comorbidities of FXS are neuropsychiatric disorders such as hyperactivity, depression and anxiety. The mutation of FMR1 in FXS disrupts production of the FMR1 gene product, the fragile mental retardation protein (FMRP). The main function of FMRP is to locally act as a translational repressor for target mRNAs and thereby regulate de novo protein synthesis and ultimately synaptic plasticity. FMRP, together with the mTOR pathway and the ERK pathway regulates expression of target mRNAsn mediated by stimulation of Group I metabotropic glutamate receptors (mGluR) and thereby regulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) internalisation and thus long term depression (LTD). LTD is a form of synaptic plasticity which is involved in learning and memory. Lack of FMRP leads to exaggerated mGluR dependant LTD, which accounts for most of FXS pathogenesis.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. ''P54764 (EPHA4_HUMAN)''; UniProt,
  2. Westmark CJ; ''FMRP: a triple threat to PSD-95.''; Front Cell Neurosci, 2013 PubMed Europe PMC
  3. Lüscher C, Huber KM; ''Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease.''; Neuron, 2010 PubMed Europe PMC
  4. Resh MD; ''Fyn, a Src family tyrosine kinase.''; Int J Biochem Cell Biol, 1998 PubMed Europe PMC
  5. Liu B, Li L, Chen J, Wang Z, Li Z, Wan Q; ''Regulation of GABAA receptors by fragile X mental retardation protein.''; Int J Physiol Pathophysiol Pharmacol, 2013 PubMed Europe PMC
  6. Song MS, Rossi JJ; ''Molecular mechanisms of Dicer: endonuclease and enzymatic activity.''; Biochem J, 2017 PubMed Europe PMC
  7. Huber KM, Klann E, Costa-Mattioli M, Zukin RS; ''Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism.''; J Neurosci, 2015 PubMed Europe PMC
  8. Guo W, Ceolin L, Collins KA, Perroy J, Huber KM; ''Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model.''; Cell Rep, 2015 PubMed Europe PMC
  9. Borrie SC, Brems H, Legius E, Bagni C; ''Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways.''; Annu Rev Genomics Hum Genet, 2017 PubMed Europe PMC
  10. ''UniProtKB - A7KAX9 (RHG32_HUMAN)''; UniProt,
  11. ''ALDH5A1 aldehyde dehydrogenase 5 family member A1 [ Homo sapiens (human) ]''; NCBI Gene, 2019
  12. Sabiha Abekhoukh, H. Bahar Sahin, Mauro Grossi, Samantha Zongaro, Thomas Maurin, Irene Madrigal, Daniele Kazue-Sugioka, Annick Raas-Rothschild, Mohamed Doulazmi, Pilar Carrera, Andrea Stachon, Steven Scherer, Maria Rita Drula Do Nascimento, Alain Trembleau, Ignacio Arroyo, Peter Szatmari, Isabel M. Smith, Montserrat Milà, Adam C. Smith, Angela Giangrande, Isabelle Caillé, Barbara Bardoni; ''New insights into the regulatory function of CYFIP1 in the context of WAVE- and FMRP-containing complexes''; Google Scholar, 2017
  13. Boykevisch S, Zhao C, Sondermann H, Philippidou P, Halegoua S, Kuriyan J, Bar-Sagi D; ''Regulation of ras signaling dynamics by Sos-mediated positive feedback.''; Curr Biol, 2006 PubMed Europe PMC
  14. ''GAD1 glutamate decarboxylase 1 [ Homo sapiens (human) ]''; NCBI Gene, 2019
  15. Hennig A, Markwart R, Esparza-Franco MA, Ladds G, Rubio I; ''Ras activation revisited: role of GEF and GAP systems.''; Biol Chem, 2015 PubMed Europe PMC
  16. Xu W, Schlüter OM, Steiner P, Czervionke BL, Sabatini B, Malenka RC; ''Molecular dissociation of the role of PSD-95 in regulating synaptic strength and LTD.''; Neuron, 2008 PubMed Europe PMC
  17. Chowdhury S, Shepherd JD, Okuno H, Lyford G, Petralia RS, Plath N, Kuhl D, Huganir RL, Worley PF; ''Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking.''; Neuron, 2006 PubMed Europe PMC
  18. Joseph Vithayathil, Joanna Pucilowska, Gary E. Landreth; ''ERK/MAPK signaling and''; ScienceDirect, 2018
  19. Bhakar AL, Dölen G, Bear MF; ''The pathophysiology of fragile X (and what it teaches us about synapses).''; Annu Rev Neurosci, 2012 PubMed Europe PMC
  20. Kong, Sek Won, Mustafa Sahin, Christin D. Collins, Mary H. Wertz, Malcolm G. Campbell, Jarrett D. Leech, Dilja Krueger, Mark F. Bear, Louis M. Kunkel, Isaac S. Kohane.; ''Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis''; Molecular Autism, 2014
  21. Westmark CJ, Sokol DK, Maloney B, Lahiri DK; ''Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.''; Mol Psychiatry, 2016 PubMed Europe PMC
  22. Chen BS, Roche KW; ''Regulation of NMDA receptors by phosphorylation.''; Neuropharmacology, 2007 PubMed Europe PMC
  23. Yang T, Zhao H, Lu C, Li X, Xie Y, Fu H, Xu H; ''Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome.''; Neural Plast, 2016 PubMed Europe PMC
  24. Yoshii A, Constantine-Paton M; ''Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease.''; Dev Neurobiol, 2010 PubMed Europe PMC
  25. Katarzyna Switona, Katarzyna Kotulskab, Aleksandra Janusz-Kaminskaa, Justyna Zmorzynskaa, Jacek Jaworski; ''Molecular Neurobiology of mTOR''; Google Scholar, 2017
  26. Wang H, Fukushima H, Kida S, Zhuo M; ''Ca2+/calmodulin-dependent protein kinase IV links group I metabotropic glutamate receptors to fragile X mental retardation protein in cingulate cortex.''; J Biol Chem, 2009 PubMed Europe PMC
  27. Kim SW, Cho KJ; ''Activity-dependent alterations in the sensitivity to BDNF-TrkB signaling may promote excessive dendritic arborization and spinogenesis in fragile X syndrome in order to compensate for compromised postsynaptic activity.''; Med Hypotheses, 2014 PubMed Europe PMC
  28. Huang J, Ikeuchi Y, Malumbres M, Bonni A; ''A Cdh1-APC/FMRP Ubiquitin Signaling Link Drives mGluR-Dependent Synaptic Plasticity in the Mammalian Brain.''; Neuron, 2015 PubMed Europe PMC
  29. Robert B. Denman; ''Modeling Fragile X Syndrome''; Google Books, 2011
  30. Mark F. Bear, Kimberly M. Huber, Stephen T. Warren; ''The mGluR theory of fragile X mental retardation''; Google Scholar, 2004
  31. Uzunova G, Hollander E, Shepherd J; ''The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.''; Curr Neuropharmacol, 2014 PubMed Europe PMC
  32. Kang SJ, Kaang BK; ''Metabotropic glutamate receptor dependent long-term depression in the cortex.''; Korean J Physiol Pharmacol, 2016 PubMed Europe PMC
  33. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ; ''Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.''; Genes Brain Behav, 2012 PubMed Europe PMC
  34. Sethna F, Moon C, Wang H; ''From FMRP function to potential therapies for fragile X syndrome.''; Neurochem Res, 2014 PubMed Europe PMC
  35. Mark F. Bear, M. Huber, Stephen T. Warren; ''The mGluR theory of fragile X mental retardation''; Google Scholar, 2004
  36. Ye K, Snyder SH; ''PIKE GTPase: a novel mediator of phosphoinositide signaling.''; J Cell Sci, 2004 PubMed Europe PMC
  37. Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, Li H, Sala C, Hayashi Y; ''The postsynaptic density proteins Homer and Shank form a polymericnetwork structure.''; Cell, 2009 PubMed Europe PMC
  38. Zhang L, Alger BE; ''Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome.''; J Neurosci, 2010 PubMed Europe PMC
  39. Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, Li H, Sala C, Hayashi Y; ''The postsynaptic density proteins Homer and Shank form a polymeric network structure.''; Cell, 2009 PubMed Europe PMC
  40. LF Reichard; ''Neurotrophin-regulated signalling pathways''; Google Scholar, 2006
  41. Luo J, Manning BD, Cantley LC; ''Targeting the PI3K-Akt pathway in human cancer: rationale and promise.''; Cancer Cell, 2003 PubMed Europe PMC
  42. Bear MF, Huber KM, Warren ST; ''The mGluR theory of fragile X mental retardation.''; Trends Neurosci, 2004 PubMed Europe PMC
  43. Mark F Bear, Kimberly M Huber, Stephen T Warren; ''The mGluR theory of fragile x mental retardation''; Google Scholar, 2004
  44. Li Y, Tang W, Zhang LR, Zhang CY; ''FMRP regulates miR196a-mediated repression of HOXB8 via interaction with the AGO2 MID domain.''; Mol Biosyst, 2014 PubMed Europe PMC
  45. Westmark CJ, Malter JS; ''FMRP mediates mGluR5-dependent translation of amyloid precursor protein.''; PLoS Biol, 2007 PubMed Europe PMC
  46. Henley JM, Wilkinson KA; ''AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging.''; Dialogues Clin Neurosci, 2013 PubMed Europe PMC
  47. Santoro MR, Bray SM, Warren ST; ''Molecular mechanisms of fragile X syndrome: a twenty-year perspective.''; Annu Rev Pathol, 2012 PubMed Europe PMC
  48. Denise Cook, Scott A. Cameron, Emma V. Jones; ''Fragile X Mental Retardation Protein: Regulator of Specific mRNAs or Master Regulator of Global Translation?''; Google Scholar, 2010
  49. Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, Hu JH, Worley PF, Gibson JR, Huber KM; ''Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.''; Nat Neurosci, 2012 PubMed Europe PMC
  50. Ronesi JA, Huber KM; ''Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation.''; J Neurosci, 2008 PubMed Europe PMC
  51. Karsten Schmidt; ''Analysis of the Structure and Function of Protein Phosphatase 2A ''; Institutional Repository of the University of Basel, 2004
  52. DaSilva LL, Wall MJ, P de Almeida L, Wauters SC, Januário YC, Müller J, Corrêa SA; ''Activity-Regulated Cytoskeleton-Associated Protein Controls AMPAR Endocytosis through a Direct Interaction with Clathrin-Adaptor Protein 2.''; eNeuro, 2016 PubMed Europe PMC
  53. Leboucher A, Pisani DF, Martinez-Gili L, Chilloux J, Bermudez-Martin P, Van Dijck A, Ganief T, Macek B, Becker JAJ, Le Merrer J, Kooy RF, Amri EZ, Khandjian EW, Dumas ME, Davidovic L; ''The translational regulator FMRP controls lipid and glucose metabolism in mice and humans.''; Mol Metab, 2019 PubMed Europe PMC
  54. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N; ''4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.''; Genes Dev, 1998 PubMed Europe PMC
  55. ''ALDH3A2 aldehyde dehydrogenase 3 family member A2 [ Homo sapiens (human) ]''; NCBI Gene, 2019
  56. Robert Malenka; '' Intercellular Communication in the Nervous System''; Google Books, 2010
  57. ''SLC6A1 solute carrier family 6 member 1 [ Homo sapiens (human) ]''; NCBI Gene, 2019
  58. Lai MM, Hong JJ, Ruggiero AM, Burnett PE, Slepnev VI, De Camilli P, Snyder SH; ''The calcineurin-dynamin 1 complex as a calcium sensor for synaptic vesicle endocytosis.''; J Biol Chem, 1999 PubMed Europe PMC
  59. Gao F, Qi L, Yang Z, Yang T, Zhang Y, Xu H, Zhao H; ''Impaired GABA Neural Circuits Are Critical for Fragile X Syndrome.''; Neural Plast, 2018 PubMed Europe PMC
  60. Michael R. Santoro, Steven M. Bray, Stephen T. Warren; ''Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective''; Google Scholar, 2012
  61. Xing Liu, Qin-Hua Gu, Kaizheng Duan, Zheng Li; ''NMDA Receptor-Dependent LTD Is Required for Consolidation But Not Acquisition of Fear Memory''; The Journal of Neurosicence, 2014
  62. ''UniProtKB - Q9Y566 (SHAN1_HUMAN)''; UniProt,
  63. Yun SH, Trommer BL; ''Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.''; J Neurosci Res, 2011 PubMed Europe PMC
  64. '' ABAT 4-aminobutyrate aminotransferase [ Homo sapiens (human) ]''; NCBI Gene, 2019
  65. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF; ''Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.''; Recent Prog Horm Res, 2001 PubMed Europe PMC
  66. Kawaguchi K, Morita M; ''ABC Transporter Subfamily D: Distinct Differences in Behavior between ABCD1-3 and ABCD4 in Subcellular Localization, Function, and Human Disease.''; Biomed Res Int, 2016